Multiple daily injections in young patients using the ezy-BICC bolus insulin calculation card, compared to mixed insulin and CSII
- PMID: 19076301
- DOI: 10.1111/j.1399-5448.2008.00484.x
Multiple daily injections in young patients using the ezy-BICC bolus insulin calculation card, compared to mixed insulin and CSII
Abstract
Objective: To describe the easy bolus insulin calculation card (ezy-BICC) approach to multiple daily injections and to compare in an observational study, the haemoglobin A1c (HbA1c) achieved while using ezy-BICC, mixed insulin injections and continuous subcutaneous insulin infusion (CSII).
Methods: HbA1c results from 7121 clinic visits by 573 patients aged 1-20 yr using the three methods between June 2000 and July 2008 were reviewed.
Results: For mixed insulin median, mean and SD HbA1c were 8.3%, 8.3%, 1.33, for ezy-BICC, 7.6%, 7.7%, 1.40, and for CSII, 7.6%, 7.8%, 1.31. HbA1c increases with age significantly more in those using CSII (p < 0.001). By regression, compared with mixed insulin HbA1c is 0.7% lower using ezy-BICC (p < 0.018) and 1.5% lower using CSII (p < 0.001). For patients using CSII compared with <6 yr, those 6-12 yr have HbA1c 0.7% higher (p < 0.001), 12-15 yr 1.0% higher (p < 0.001) and 15-20 yr 1.2% higher (p < 0.001). For subjects >12 yr, HbA1c is lower while using ezy-BICC than CSII. HbA1c increases 0.2% per yr following diagnosis for 2.8 yr. In those who change from mixed insulin to ezy-BICC after this time, the mean HbA1c is 0.5% lower by 9 months, 0.7% lower at 21 months and 0.6% lower at 24 months (p < 0.05).
Conclusions: The ezy-BICC system is inexpensive and convenient and allows patients to vary meal size. Subjects achieve lower HbA1c while using CSII and ezy-BICC MDI than with mixed insulin. Very young subjects achieve excellent HbA1c using CSII, but for 12 to 20 yr-old patients, ezy-BICC results in lower HbA1c than CSII for a lower cost.
Similar articles
-
Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.Health Technol Assess. 2018 Aug;22(42):1-112. doi: 10.3310/hta22420. Health Technol Assess. 2018. PMID: 30109847 Free PMC article. Clinical Trial.
-
Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.Acta Diabetol. 2019 Sep;56(9):973-980. doi: 10.1007/s00592-019-01326-5. Epub 2019 Apr 3. Acta Diabetol. 2019. PMID: 30945047
-
Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.BMJ. 2019 Apr 3;365:l1226. doi: 10.1136/bmj.l1226. BMJ. 2019. PMID: 30944112 Free PMC article. Clinical Trial.
-
Cost-effectiveness of continuous subcutaneous insulin infusion (CSII) in children: illusion or delusion?Pediatr Diabetes. 2006 Aug;7 Suppl 4:39-44. doi: 10.1111/j.1399-543X.2006.00168.x. Pediatr Diabetes. 2006. PMID: 16774617 Review.
-
[An overview of so far published analyses comparating the effectiveness of the treatment with insulin pump and multiple daily injections in type 1 diabetes mellitus].Vnitr Lek. 2012 Feb;58(2):89-93. Vnitr Lek. 2012. PMID: 22463086 Review. Czech.
Cited by
-
Bolus calculators.J Diabetes Sci Technol. 2014 Sep;8(5):1035-41. doi: 10.1177/1932296814532906. Epub 2014 May 19. J Diabetes Sci Technol. 2014. PMID: 24876436 Free PMC article. Review.
-
Bolus Calculator Safety Mandates a Need for Standards.J Diabetes Sci Technol. 2017 Jan;11(1):3-6. doi: 10.1177/1932296816685475. Epub 2016 Dec 20. J Diabetes Sci Technol. 2017. PMID: 28264178 Free PMC article. No abstract available.
-
Comparison of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injections in Pediatric Type 1 Diabetes: A Meta-Analysis and Prospective Cohort Study.Front Endocrinol (Lausanne). 2021 Mar 2;12:608232. doi: 10.3389/fendo.2021.608232. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33737909 Free PMC article.
-
Adolescents with type 1 diabetes can achieve glycemic targets on intensive insulin therapy without excessive weight gain.Endocrinol Diabetes Metab. 2022 Jul;5(4):e352. doi: 10.1002/edm2.352. Epub 2022 Jun 17. Endocrinol Diabetes Metab. 2022. PMID: 35715954 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical